Latest Regulatory Progress News

EBR Systems has landed a significant purchasing agreement with Advocate Health, the third-largest US non-profit health system, opening access for its WiSE wireless cardiac pacing technology across 69 hospitals in eight states.

Algorae Pharmaceuticals has scaled its AI-driven drug synergy platform from one to 18 anchor drugs, generating over 9 million predictions and identifying thousands of promising combinations for cancer and other diseases.

Maronan Metals has reported robust assay results from its 2025 infill drilling, revealing significant shallow copper-gold and silver-lead mineralisation that could boost early mining inventory. A revised boxcut design also promises to cut excavation volumes substantially.

The ACCC has given the green light for Zurich’s acquisition of ClearView, clearing a major regulatory hurdle. With board and Crescent Capital Partners backing the deal, the transaction edges closer to completion, pending further approvals.

Pacific Edge edges closer to a Medicare breakthrough with a draft Local Coverage Determination proposing coverage for its Cxbladder Triage and Triage Plus tests, potentially unlocking reimbursement for over 66 million US patients.

Syntara Limited offers existing shareholders a discounted share purchase plan to raise about $2 million, following a recent $8 million institutional placement to fund clinical trials and licensing.

Anson Resources and POSCO Holdings have sealed a binding deal for a $7.2 million lithium extraction demonstration plant at Green River, advancing the project from concept to operational validation.

Atlas Arteria reported a resilient 2025 with 9.3% EBITDA growth and steady toll revenue, while its Board unanimously urged investors to reject IFM’s unsolicited takeover offer, citing undervaluation and onerous conditions.

Nexsen has secured a strategic partnership with GHK Hospital Limited in Hong Kong, marking a significant step in validating and commercialising its rapid point-of-care diagnostics across North Asia.

Aguia Resources has addressed all regulatory queries for its Tres Estradas phosphate mine operating licence, with final approval expected soon. The project remains on track for mid-May operational readiness, while its Pampafos fertiliser offers a significant cost edge amid supply shortages in Southern Brazil.

Arovella Therapeutics has named Dr Nicole Van Der Weerden as acting CEO following Dr Michael Baker’s departure, positioning her to steer the company through the critical phase I trial of its CAR-iNKT therapy ALA-101.

Sky Metals accelerates development of its Tallebung tin-tungsten-silver project with NSW State Significant Development approval process initiated and over 500 drill holes underpinning an updated resource and feasibility study.